Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash from Operations: 2022-2024

Historic Cash from Operations for Lexeo Therapeutics (LXEO) over the last 3 years, with Dec 2024 value amounting to -$81.2 million.

  • Lexeo Therapeutics' Cash from Operations rose 15.91% to -$14.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$59.5 million, marking a year-over-year change of. This contributed to the annual value of -$81.2 million for FY2024, which is 36.40% down from last year.
  • Per Lexeo Therapeutics' latest filing, its Cash from Operations stood at -$81.2 million for FY2024, which was down 36.40% from -$59.5 million recorded in FY2023.
  • Lexeo Therapeutics' Cash from Operations' 5-year high stood at -$54.6 million during FY2022, with a 5-year trough of -$81.2 million in FY2024.
  • Over the past 3 years, Lexeo Therapeutics' median Cash from Operations value was -$59.5 million (recorded in 2023), while the average stood at -$65.1 million.
  • Data for Lexeo Therapeutics' Cash from Operations shows a maximum YoY crashed of 36.40% (in 2024) over the last 5 years.
  • Over the past 3 years, Lexeo Therapeutics' Cash from Operations (Yearly) stood at -$54.6 million in 2022, then fell by 9.05% to -$59.5 million in 2023, then slumped by 36.40% to -$81.2 million in 2024.